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Abstract
We tested the hypothesis that irregular menstruation predicts lower risk for ovarian cancer, 
possibly due to less frequent ovulation. We conducted a 50-year prospective study of 15,528 
mothers in the Child Health and Development Studies cohort recruited from the Kaiser Foundation 
Health Plan from 1959 to 1966. Irregular menstruation was classified via medical record and self-
report at age 26. We identified 116 cases and 84 deaths due to ovarian cancer through 2011 via 
linkage to the California Cancer Registry and Vital Statistics. Contrary to expectation, women with 
irregular menstrual cycles had a higher risk of ovarian cancer incidence and mortality over the 50-
year follow-up. Associations increased with age (p <0.05). We observed a 2-fold increased 
incidence and mortality by age 70 (95% confidence interval [CI] = 1.1, 3.4) rising to a 3-fold 
increase by age 77 (95% CI = 1.5, 6.7 for incidence; 95% CI = 1.4, 5.9 for mortality). We also 
found a 3-fold higher risk of mortality for high-grade serous tumors (95% CI = 1.3, 7.6) that did 
not vary by age. This is the first prospective study to show an association between irregular 
menstruation and ovarian cancer—we unexpectedly found higher risk for women with irregular 
cycles. These women are easy to identify and many may have polycystic ovarian syndrome. 
Classifying high-risk phenotypes such as irregular menstruation creates opportunities to find novel 
early biomarkers, refine clinical screening protocols and potentially develop new risk reduction 
strategies. These efforts can lead to earlier detection and better survival for ovarian cancer.
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Ovarian cancer is the fifth leading cause of cancer death for women in the US, estimated to 
claim over 14,000 lives in 2015. The lack of specific early symptoms, aggressiveness of 
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some of the histopathologic sub-types and need for more effective screening and treatment 
strategies is evidenced by a dismal 5-year overall survival rate (45%) for all stages.2 Ovarian 
cancer symptoms are nonspecific, and patients frequently come to diagnosis with advanced-
stage disease.3 The need for identifiable risk factors and early markers of disease is critical 
for improving screening, treatment and survival and for providing insight about disease 
etiology and progression.
About 90% of ovarian cancer cases are epithelial and the remaining originate from sex cord-
stromal cells (5–6%) or from germ cells (2–3%).4 Thus, most epidemiologic and clinical 
studies report findings that refer to epithelial ovarian cancer which is comprised of 
heterogeneous histologic subtypes, including serous (30–70%), endometrioid (10–20%), 
mucinous (5–20%) and clear cell (3–10%).4 Although epithelial ovarian tumors are situated 
in the ovary, recent molecular genetic and morphologic studies suggest they may originate 
primarily in the fallopian tube.5–7
The strongest risk factors for ovarian cancer are age, family history and germline mutations 
BRCA1, BRCA2 and other genes that have variable penetrance for disease. In a 
comprehensive screen of sequential ovarian cancer subjects, 24% of them carried a germline 
loss-of-function mutation, suggesting heritable ovarian cancer in just over one-fifth of cases.
8
 The remainder appear to be sporadic events. Several other risk characteristics, such as 
pregnancy, parity, infertility and other reproductive characteristics, are of more modest 
magnitude and have been identified with varying degrees of consistency.
A major focus of research has involved reproductive and hormonal factors. Nulliparity, 
infertility, early menarche and late menopause are associated with increased risk of ovarian 
cancer, although findings are not consistent.3,9–11 High parity, oral contraceptive use and 
bilateral prophylactic salpingooophorectomy are widely established as protective factors.9,12
Collectively, these epidemiological studies support the incessant ovulation hypothesis which 
suggests that chronic lifetime ovulation, uninterrupted by pregnancy, increases ovarian 
cancer risk. Adding confusion is contradictory epidemiologic evidence from a small study 
that showed women with polycystic ovarian syndrome, who experience chronic anovulation 
and irregular menstrual cycles, are at increased, rather than decreased, risk of ovarian cancer.
13
 Several studies have examined the influence of shorter, longer and irregular cycles on 
ovarian cancer risk. However, findings are inconclusive and show both increased and 
reduced risk associated with irregular cycles.14–16 The present study provides the first 
evidence in a large prospective study with long-term follow-up extending through the period 
of risk to help clarify the relation of menstrual irregularity to risk of ovarian cancer.
Material and Methods
Study population
The Child Health and Development Studies (CHDS) cohort, initiated in 1959, recruited 
nearly all pregnant women (over 98%) receiving prenatal care from the Kaiser Foundation 
Health Plan in the San Francisco East Bay area. In all, 15,528 women were enrolled during 
the 7-year recruitment period from 1959 until 1966, with deliveries extending into 1967.17 
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The CHDS cohort incorporated multiple race/ethnic groups with a broad socio-economic 
base and uniform access to health care. Pre-existing maternal conditions and clinical 
measures (e.g., prenatal and obstetric) were abstracted from medical records. Demographic 
information and health-related behavior were collected from in-person interviews for all 
pregnancies, generally early in the first trimester. The institutional review board of the 
Public Health Institute approved the study protocol and informed consent was obtained from 
all participants.
Cohort surveillance
Prospective surveillance has continued for 5 decades by annual linkage to: i) the California 
Department of Motor Vehicles, for a history of residence to identify the population at risk 
for morbidity and mortality, ii) the California Department of Vital Statistics, for identifying 
deaths and cause of death18,19 and iii) the California Cancer Registry, for identifying cancer 
diagnoses.20–23
CHDS mothers are regularly matched to these sources using an accumulated name and 
address history for each cohort member. This protects against establishing false matches and 
failing to identify true matches. Surveillance efforts routinely identify over 90% of CHDS 
mothers.
Ovary cancer mortality
Results from linkage to the California Vital Status files were used to append year of death 
and underlying cause. Since follow-up of the cohort spanned over 50 years, codes for the 
underlying cause of death from several ICD revisions were used to define ovarian cancer 
death, including 175 for ICD-7; 183 for ICD-8 and 29 and C56 for ICD-10. Linkages to the 
National Death Index to evaluate the completeness of mortality surveillance have yielded 
very few missed cases. California Vital Statistics linkage through 2011 yielded 84 ovarian 
cancer deaths.
Ovary cancer incidence
Results from linkage to the California Cancer Registry were used to append ovarian cancer 
diagnosis, year of diagnosis and tumor histology and grade. The California Cancer Registry 
has established that its cancer coverage is >99% complete after a lag time of about 2 years.24 
Life table analyses estimating expected numbers of breast (unpublished) and testicular 
cancer cases20 show close comparability to observed numbers. Linkage to the California 
Cancer Registry through 2011 identified 116 cases of ovarian cancer.
Irregular menstruation was defined as self-report or physician report of irregular menstrual 
cycles, self or physician report of long cycles (>35 days); or physician coded 
oligomenorrhea, anovulatory cycles or irregular menses.18,25 The time frame captured by 
this measure refers to an assessment of menstrual cycle irregularity that encompasses the 
time between menarche and study enrollment. Thus, this measures estimates chronic 
menstrual irregularity in the CHDS over an extended time period, 14 years on average.
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Covariates were derived from information provided during pregnancy interview and from 
medical records. Race was categorized as Caucasian, African-American, Hispanic, Asian or 
other. Age was based on reported age at entry to the study. Parity reflects number of live-
born births prior to the observed pregnancy. Cigarette smoking during pregnancy was based 
on self-report at entry. BMI was calculated from weight (kg) divided by height (m) squared, 
measured at first prenatal visit.
Oral contraceptive use, age at menarche and subfertility were determined from interview and 
from medical record review. Subfertility was defined as physician-coded infertility or 
participant-reported “trouble getting pregnant”. Since all women in the cohort were 
pregnant, these characteristics were assessed as subfertility rather than infertility. Age at 
menarche was evaluated as early (≤11 years) and late (≥15 years) versus the reference Group 
(12–14 years). Oral contraceptive use, administration of fertility drugs and subfertility were 
coded as yes versus no and refer to the period just prior to the observed pregnancy.
Analysis methods
Kaplan-Meier curves of cumulative ovarian cancer survival and disease-free probability 
were created to examine the association of irregular menstrual cycles. Age at diagnosis and 
at death or follow-up was calculated based on year of diagnosis, death or last contact; and, 
year and age at entry. Hazard ratios (HRs) were calculated using Cox proportional hazards 
models to estimate ovarian cancer associations for irregular cycles accounting for potential 
confounding by covariates. The proportional hazards assumption was tested by including a 
cross-product term between irregular cycles and age at event. Analysis was performed using 
SAS 9.3.
Results
Among the 15,528 mothers enrolled in the CHDS, we identified 116 cases of ovarian cancer 
and 84 ovarian cancer deaths during the 501 years of cohort surveillance. The median age at 
diagnosis was 63 years, ranging from 27 to 86 years. The median age at case death was 69 
years, ranging from 27 to 90 years. Cases were predominantly classified as epithelial tumors
—only one was identified as a sex cord-stromal tumor and an additional four had unknown 
histological classification. The distribution of histologic subtype in the CHDS was similar to 
that reported elsewhere4: 45% serous, 7% mucinous, 12% endometrioid, 4% clear cell, 12% 
unclassified epithelial and 2% miscellaneous. Serous tumors represented 67% of classified 
histopathologic sub-types. This distribution was not different between women with regular 
and irregular cycles.
The median age at study pregnancy was 26 years, ranging from 14 to 48 years and most 
women were multiparous (60%) when they enrolled. The majority was Caucasian (67%), 
and there was also a large representation of African Americans (24%). The prevalence of 
women with irregular menstrual cycles was 13% and the prevalence of oral contraceptive 
use was low, slightly >4%, in keeping with the practice of the time. Table 1 provides the 
prevalence of these characteristics in the CHDS as well as age-adjusted rates of ovarian 
cancer incidence and mortality.
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Figure 1 presents cumulative probability for ovarian cancer survival (Fig. 1a) and disease-
free status (Fig. 1b) by cycle irregularity in CHDS mothers. Figure 1 shows markedly lower 
survival for women with irregular cycles beginning at age 70 and increasing with age.
Table 2 provides HRs from age, parity and race-adjusted models; and, from fully adjusted 
models. We found significant and positive age dependence of similar magnitude for both 
mortality (β = 0.06, p 5 0.04) and incidence (β = 0.07, p = 0.01), demonstrating an 
increasing association for irregular cycles with advancing age. These associations were 
unchanged by adjustment for potential explanatory covariates.
There were 30 diagnoses of high grade (grade ≥ 2) serous ovarian cancer and 23 deaths. The 
association with irregular cycles was substantial and significant for high grade serous death 
(HR = 3.1; 95% confidence interval [CI] = 1.3, 7.6) and still considerable but marginally 
significant for high grade serous incidence (HR = 2.1; 95% CI = 0.9, 5.0). This association 
was not age-dependent.
Discussion
Principal findings
Based on the incessant ovulation hypothesis, which postulates that less frequent ovulatory 
cycles reduce ovarian cancer risk, we expected that irregular cycles would be protective. 
Instead we found that irregular cycles were a marker for higher risk of ovarian cancer. 
Further, the increased risk of ovarian cancer observed for women with irregular cycles was 
significantly and positively age-dependent, demonstrating substantial risk beginning at age 
70, suggesting that the effects of irregular cycles may require the susceptibility of advanced 
age to enhance risk.
Context
A number of studies have reported ovarian cancer associations with menstrual cycle 
variability,14,15,26–32 and four studies have reported associations with polycystic ovary 
syndrome (PCOS)33 (and reviewed in Refs. 16,34). Findings for these studies have been 
inconsistent showing negative, positive and null associations. Three of these studies 
observed statistically significant results—two showing decreased risk14,26 and one showing 
increased risk.13 All three were based on case-control study designs and may have been 
subject to errors in recall and recall bias, differences in participant age and parity and 
differences in how irregular cycles was defined, strictly as a specific length or as variable 
lengths, and whether anovulatory cycles were included.
Strengths
This is the first prospective study showing a significant and positive ovarian cancer 
association with irregular cycles. Information about menstrual cycle variability was captured 
at a young age during the peak of reproduction and long before diagnosis of ovarian cancer, 
minimizing the potential for recall bias. The prevalence of irregular cycles (13%) in the 
CHDS is comparable to that observed in other studies.35,36 The long follow-up period 
allowed for a sufficient accumulation of ovarian cancer diagnoses and deaths to examine risk 
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by age. Since all the women in our study had achieved a pregnancy, we were able to rule out 
lifetime infertility as an explanation of the observed association. Infertility occurs with 
relatively low frequency (ranging from 11% in 1965% to 6% in 2010)37 and most women 
are able to achieve a pregnancy, including those with irregular cycles or PCOS, a condition 
associated with irregular cycles.38 Thus, our results apply to the many women with regular 
and irregular cycles who do conceive.
We were able to adjust for a number of important confounders measured prospectively from 
medical records (oral contraceptive use and history of infertility) and/or from self-report 
(age at menarche, difficulty becoming pregnant) assessed at entry during early pregnancy. 
Prior studies have demonstrated strong protection against ovarian cancer for oral 
contraceptive use and higher risk for infertility (reviewed in Refs. 9, 10, 14, 39). Oral 
contraceptive use (4% in our cohort) and infertility or difficulty becoming pregnant prior to 
entry (12% in our cohort) were infrequent in the CHDS as would be expected for a cohort of 
pregnant women, enrolled in the early 1960s just as the Food and Drug Administration 
approved use of oral contraception for birth control.40 Although CHDS women with 
irregular cycles were more likely to be subfertile (18% versus 11% in women with regular 
cycles), there was no evidence of interaction between irregular cycles and either oral 
contraception or subfertility in predicting ovarian cancer. Neither subfertility nor oral 
contraceptive use was a predictor; and, adjustment for these variables did not change the 
association with irregular cycles, likely due to their low prevalence in this cohort. Young age 
at menarche has also been observed to enhance ovarian cancer risk (reviewed in Ref. 9). 
However, young age at menarche (≤11 years) was not associated with ovarian cancer risk in 
the CHDS and did not confound the association with irregular cycles. None of the examined 
covariates—subfertility, timing of menarche, weight, age, race and parity—explained the 
observed increased risk for women with irregular cycles.
Limitations
It is possible that unmeasured factors account for the association we observed between 
menstrual irregularity and ovarian cancer. We do not have information about changes in 
menstrual cycle regularity or events (e.g., obstetric and gyneco-logic) and behavior after the 
study period, thus we were unable to examine the influence of these factors known to both 
increase (hormone replacement therapy [HRT]) and decrease (oral contraceptive pills [OCP] 
and tubal ligation) risk of ovarian cancer. Some of these unmeasured changes should have 
enhanced the association we observed rather than explain it, such as oral contraceptives and 
bilateral oophorectomy. Oral contraceptive use may have increased in this population over 
time regardless of menstrual cycle length as this form of birth control became increasingly 
more popular. And, it is likely that oral contraceptive use and possibly bilateral salpingo-
oophorectomy (with hysterectomy) would have been more frequent in women with irregular 
cycles to regulate unpredictable bleeding. If so, the association we observed between 
irregular cycles and ovarian cancer may be larger than we were able to estimate.
More frequent use of HRT in later life by women with irregular cycles could have 
contributed to the associations we report, although it is unclear why HRT use would be 
higher among these women. The increased risk of ovarian cancer associated with HRT use is 
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significant but moderate (HR 5 1.53; CI 1.4–1.66).41 Therefore, the frequency of HRT use 
would have to differ markedly for women with irregular cycles in order to account for the 
sizeable association we found.
Our definition of irregular cycles may capture heterogeneous biological and hormonal traits. 
Further, menstrual cycle status refers to the time between menarche and the observed 
pregnancy but we were unable to capture change in cycle variation after the study. 
Misclassifying women who became regular after the observed pregnancy would bias results 
toward the null. However, despite its lack of specificity, “irregular cycles”, as defined, is a 
strong predictor of ovarian cancer risk in the CHDS suggesting that cycle regularity in early 
reproductive life is the relevant risk factor.
Plausibility
It is possible that women with irregular cycles or PCOS have a hormonal profile that favors 
the neoplastic process through chronic unopposed estrogen, higher androgens or some other 
mechanism. The protection against ovarian cancer risk observed for oral contraception 
formulations containing only progestin and progestin-plus-estrogen supports the possibility 
that unopposed estrogen, rather than low progesterone, could be associated with increased 
risk.9,12 Alternatively, oral contraceptives may protect by reducing circulating androgen.12 
Molecular evidence also suggests that androgen synthesis and action are involved in ovarian 
cancer etiology.42 Therefore, the increased risk of ovarian cancer among PCOS women who 
express symptoms of hyperandrogenism42 is consistent with an androgen-related 
mechanism.
Prevention
This study provides new prospective evidence that woman with irregular menstrual cycles, 
who are more likely to have PCOS, are at an increased risk of ovarian cancer. If confirmed 
this will add to the burden of liability for women with PCOS who have higher risk for 
endometrial cancer,43,44 metabolic syndrome45 and cardiovascular disease (CVD), including 
prospective evidence of higher CVD risk in this cohort.18 The cooccurrence of increased risk 
for multiple diseases in women with PCOS complicates the implications for prevention. Oral 
contraception could possibly provide greater protection against ovarian cancer for women 
with PCOS compared to the general population adding to the known benefit of oral 
contraceptive use for reducing risk of endome-trial cancer.46 However, the benefit of oral 
contraceptives for women with PCOS, must be considered against the cost of potential 
adverse effects on insulin resistance, glucose intolerance and vascular risk known to be more 
frequent in these women.45 The relatively higher frequency of CVD in women (lifetime risk 
for women with optimal risk factor levels is4.1%)47 compared to ovarian cancer (lifetime 
risk is 1.3%)2 and endometrial cancer (lifetime risk is 2.8%)2 suggests that it is essential to 
give significant consideration to the individual risk for cardiovascular consequences of OCP 
use. The risk reduction in ovarian cancer associated with metformin to control diabetes 
observed in a large case-control study33 may provide a promising alternative for women 
with PCOS who are at a higher risk of diabetes. However, more research from ongoing 
prospective clinical trials is needed to confirm whether metformin protects against ovarian 
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cancer among women who do not have diabetes48 and whether there are other unforeseen, 
harmful consequences of metformin treatment.
Other factors to consider for women with PCOS are intrauterine devices (IUDs) and HRT 
use. Given the potential increased ovarian cancer risk associated with IUD use either directly 
or indirectly via increased inflammation,9 and with HRT,41 further research is needed to 
determine whether women with irregular cycles require special guidelines governing use of 
these.
Future research
Current screening procedures using trans-vaginal ultrasonography and serial assay for 
CA-125 have been relatively unsuccessful in reducing ovarian cancer mortality11,49 and have 
shown limited effectiveness for early detection.11,50,51 Developing a risk algorithm that 
integrates known risk markers such as germline mutations (e.g., BRCA), with phenotypes 
(e.g., irregular cycles) and behavioral characteristics (e.g., oral contraceptive and HRT use) 
may offer a way to improve screening targets until better biomarkers are identified. The 
identification of higher risk phenotypes such as irregular menstruation may provide 
opportunities to narrow the search for early biomarkers. However, additional work to 
understand the mechanisms underlying the association between irregular menstruation and 
ovarian cancer will be necessary in order to more specifically define the clinical phenotype 
driving this observed association.
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What’s new?
The lack of specific early symptoms in ovarian cancer, aggressiveness of some of the 
histopathologic subtypes and need for more effective screening and treatment strategies 
are evidenced by a dismal 5-year survival rate for all stages. While several studies have 
reported ovarian cancer associations with menstrual cycle variability, the findings are 
inconsistent. This study provides the first prospective evidence that women with irregular 
menstrual cycles are at higher risk of ovarian cancer. Discovering high-risk phenotypes 
such as irregular menstruation creates opportunities to find novel early biomarkers, refine 
clinical screening protocols and potentially develop new risk reduction strategies for 
ovarian cancer.
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Figure 1. 
Cumulative probability of ovarian cancer survival (a) and disease-free status (b) in CHDS 
mothers, 1959–2011.
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Table 2.
Ovarian cancer associations for irregular menstrual cycles
Age at follow-up (years)1
Mortality Incidence
HR
95% CI
HR
95% CI
Lower Upper Lower Upper
Age, parity and race adjusted
65 1.41 0.74 2.67 1.42 0.84 2.38
70 1.90 1.08 3.37 1.97 1.14 3.40
75 2.58 1.36 4.90 2.74 1.38 5.43
80 3.49 1.54 7.91 3.81 1.58 9.18
85 4.73 1.66 13.49 5.30 1.76 15.98
p values for age-dependence 0.04 0.01
Fully adjusted2
65 1.39 0.66 2.94 1.55 0.86 2.80
70 1.97 1.02 3.83 2.26 1.20 4.26
75 2.80 1.31 6.00 3.29 1.47 7.37
80 3.98 1.48 10.71 4.78 1.68 13.61
85 5.65 1.57 20.34 6.94 1.86 25.92
p values for age-dependence 0.06 0.02
1
Irregular menstrual cycle status is dichotomized as observed versus not observed at first study pregnancy. Age at follow-up is modeled as a 
continuous variable. Interactions between irregular cycles and age were significant and positive for both mortality (β 5 0.06, p 5 0.04) and 
incidence (β 5 0.07, p 5 0.01).
2
The fully adjusted models include: age (continuous), race (African-American and Asian versus all other), parity (continuous), subfertility (yes 
versus no) oral contraceptive use (yes versus no just prior to observed pregnancy), young (<12 years) and old (≥15 years) age at menarche (versus 
12–14 years), smoking during pregnancy (yes versus no), gestational weight gain (continuous) and BMI at first prenatal visit (>25 kg/m2). Point 
estimates for the age-dependent term remain essentially the same regardless of adjustment. In the fully adjusted models, the interaction term is 
estimated as: β = 0.07 for mortality and β = 0.07 for incidence; and, in the age, parity and race adjusted models, the interaction is estimated as: β = 
0.06 for mortality and β = 0.07 for incidence.
Abbreviations: 95% CI, confidence interval; HR, hazard ratio.
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